Tradestie Institutional Equity Comparison Engine

SRZN vs LYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SRZN N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs -25032.0% ยท YoY +408.6% vs -87.2%
Momentum & Technical Winner SRZN
1Y +130.6% vs -94.3% ยท 52W Pos 69% vs 1%
Options & Structure Winner SRZN
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +130.62% LYRA -94.34% Spread: +183.6 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue LYRA Revenue SRZN Op. Margin LYRA Op. Margin Margin Edge
FY2021 N/A $0M N/A -15303.5% LYRA
FY2022 $10M $0M -354.7% -4131.0% SRZN
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 $10M $0M -239.7% -6280.8% SRZN
FY2025 $0M $0M -1210.6% -7794.5% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (6) vs LYRA (1)
Institutional Metric SRZN LYRA Criterion Row Winner
Market Capitalization Scale $602.5M $2.3M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% -87.2% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% -25032.0% Higher Margin SRZN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -404.5% Higher ROE SRZN
52-Week Range Position Momentum 69% ($12โ€“$38) 1% ($0โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 66% Vol 0.33ฮฒ ยท 248% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 33.2 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite LYRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs LYRA Buy Guide
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.